Impact of modification of envelope proteins on the mechanical properties of HIV virus-like particles
Source abstract
Abstract
The mechanical interactions between virus-like particles and host cells may offer targets for new viral treatments and vaccines with modes of action that are independent of the immune system. The physical properties of structures involved govern the particle-cell interactions. While the mechanical properties of virions and mammalian cells have been widely studied, data on virus-like particles are limited. This study aimed to determine the mechanical and morphological properties of HIV-1 virus-like particles with different envelopes. Three HIV-like particles, i.e. Gagᴹ + gp150, Gagᴹ + gp140HA 2 tr, and Gagᴹ + gp120HA 2 , were produced by combining the same Gag protein shell with different trimeric glycoprotein envelopes. The particles’ spring constant, breaking force, and dimensions were determined using atomic force microscopy, and the elastic modulus was quantified using finite element analysis. Spring constant, elastic modulus, and breaking force were higher for Gagᴹ + gp140HA 2 tr and Gagᴹ + gp120HA 2 than for Gagᴹ + gp150. The particle height was smaller for Gagᴹ + gp120HA 2 than for Gagᴹ + gp150 and Gagᴹ + gp140HA 2 tr. Possible mechanisms underlying the increase of the particles’ stiffness and mechanical strength are the inclusion of the influenza virus HA transmembrane domain in the HIV Env protein, and the lower expression and packing density of Env in Gagᴹ + gp140HA 2 tr and Gagᴹ + gp120HA 2 compared to Gagᴹ + gp150 found previously. Upon confirmation, the proposed mechanisms offer potential to tailor the mechanics of HIV virus-like particles and guide mechanical interactions between VLPs and host cells towards improving vaccines. • Influenza protein and lower Env expression may raise HIV VLP stiffness and strength • Influenza protein and Env expression likely mechanisms to tailor HIV VLP mechanics • Envelope mechanics can guide VLP design for novel vaccines and targeted therapies
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: HIV Research and Treatment · HIV-related health complications and treatments · Force Microscopy Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Modeling and simulation of the mechanical response from nanoindentation test of DNA-filled viral capsids10.1007/s10867-013-9297-9 ↗
2. Rational design of DNA-Expressed stabilized native-like HIV-1 envelope trimers10.1016/j.celrep.2018.08.051 ↗
3. Recent experimental advances in probing the colloidal properties of viruses10.1016/j.cocis.2023.101703 ↗
4. Structural organization of authentic, mature HIV-1 virions and cores10.1093/emboj/cdg143 ↗
5. Percolation theory reveals biophysical properties of virus-like particles10.1021/acsnano.1c01882 ↗
6. Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T Cell Inflamed” Tumors10.3389/fimmu.2019.02353 ↗
7. Physical virology: from virus self-assembly to particle mechanics10.1002/wnan.1613 ↗
8. Manipulation of the mechanical properties of a virus by protein engineering10.1073/pnas.0708017105 ↗
9. Production of HIV-1-based virus-like particles for vaccination: achievements and limits10.1007/s00253-019-10038-3 ↗
10. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice10.1371/journal.pone.0173352 ↗
11. Immunogenicity of HIV-1 vaccines expressing chimeric envelope glycoproteins on the surface of Pr55 gag virus-like particles
12. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates10.3389/fmicb.2023.1065609 ↗
13. Probing and pressing surfaces of hepatitis C virus-like particles10.1016/j.jcis.2019.03.022 ↗
14. Virus-like particle vaccines: immunology and formulation for clinical translation10.1080/14760584.2018.1516552 ↗
15. HIV-1-cellular interactions analyzed by single virus tracing10.1007/s00249-008-0322-z ↗
16. Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility10.1038/s41467-024-54373-0 ↗
17. Production of virus-like particles for vaccines10.1016/j.nbt.2017.07.010 ↗
18. Determination of the size of HIV using adenovirus Type-2 as an internal length marker10.1016/0166-0934(94)90087-6 ↗
19. Nonlinear finite-element analysis of nanoindentation of viral capsids10.1103/PhysRevE.75.031901 ↗
20. HIV-1-based virus-like particles that morphologically resemble mature, infectious HIV-1 virions10.3390/v11060507 ↗
21. Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine10.1016/j.vaccine.2007.09.061 ↗
22. Virus receptors: binding, adhesion strengthening, and changes in viral structure10.1128/jvi.68.1.1-5.1994 ↗
23. Bacteriophage capsids: tough nanoshells with complex elastic properties10.1073/pnas.0308198101 ↗
24. Topography, spike dynamics, and nanomechanics of individual native SARS-CoV-2 virions10.1021/acs.nanolett.0c04465 ↗
25. A stiffness switch in HIV10.1529/biophysj.106.093914 ↗
26. Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-infected lymphocytes10.1128/JVI.77.22.11896-11909.2003 ↗
27. Bending and puncturing the influenza lipid envelope10.1016/j.bpj.2010.12.3701 ↗
28. Structural insight into African horsesickness virus infection10.1128/JVI.00517-12 ↗
29. Atomic force microscopy observation and characterization of single virions and virus-like particles by nano-indentation10.1016/j.coviro.2016.05.002 ↗
30. Nanoindentation studies of full and empty viral capsids and the effects of capsid protein mutations on elasticity and strength10.1073/pnas.0601744103 ↗
31. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity10.1128/JVI.78.2.1026-1031.2004 ↗
32. Localization of deformation in thin shells under indentation10.1039/c3sm50279a ↗
33. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers10.1186/s12951-021-00806-7 ↗
34. Virion stiffness regulates immature HIV-1 entry10.1186/1742-4690-10-4 ↗
35. Soluble expression of Plasmodium falciparum Glutamine synthetase and three-dimensional structure by single particle reconstruction
36. Accelerating HIV-1 VLP production using stable High five insect cell pools10.1002/biot.202000391 ↗
37. Mechanical tuning of virus-like particles10.1016/j.jcis.2022.12.090 ↗
38. Mechanical disassembly of human picobirnavirus like particles indicates that cargo retention is tuned by the RNA-coat protein interaction10.1039/D3NH00195D ↗
39. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery10.1002/btm2.10049 ↗
40. How to perform a nanoindentation experiment on a virus10.1007/978-1-61779-282-3_14 ↗
41. Scaffold expulsion and genome packaging trigger stabilization of herpes simplex virus capsids10.1073/pnas.0901514106 ↗
42. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae10.1073/pnas.082281199 ↗
43. Effect of envelope proteins on the mechanical properties of influenza virus10.1074/jbc.M112.412726 ↗
44. Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide10.1186/s12951-018-0363-0 ↗
45. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design10.1016/j.celrep.2015.03.047 ↗
46. Probing the impact of loading rate on the mechanical properties of viral nanoparticles10.1016/j.micron.2012.04.011 ↗
47. Strain-stiffening universality in composite hydrogels and soft tissues10.1038/s41567-025-02869-x ↗
48. Quantitative elasticity mapping of Submicron Silica Hollow particles by PeakForce QNM AFM mode10.3390/nano13131916 ↗
49. Virus-like particles nanoreactors: from catalysis towards bio-applications10.1039/D3TB01112G ↗
50. Hepatitis B core-based virus-like particles: a platform for vaccine development in plants
51. Prime-Boost immunizations with DNA, modified Vaccinia Virus Ankara, and protein-based vaccines elicit robust HIV-1 tier 2 neutralizing antibodies against the CAP256 superinfecting Virus10.1128/JVI.02155-18 ↗
52. Deciphering the thermal stability of bacteriophage MS2-Derived virus-like particle and its engineered variant10.1021/acsbiomaterials.4c00770 ↗
53. Stepwise reversible nanomechanical buckling in a viral capsid10.1039/C6NR06598H ↗
54. Virus-like particles for the prevention of human papillomavirus-associated malignancies10.1586/erv.12.151 ↗
55. Stability and integrity of self-assembled bovine parvovirus virus-like particles (BPV-VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment10.1186/s12985-024-02322-0 ↗
56. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail10.1128/JVI.78.7.3429-3435.2004 ↗
57. On virus growth and form10.1016/j.physrep.2019.12.005 ↗
58. Virus-like particles as drug delivery vectors10.18388/abp.2016_1275 ↗
59. The strain-stiffening critical exponents in polymer networks and their universality10.1063/5.0280785 ↗
60. Tuning the mechanical properties of silica microcapsules10.1039/c0cp00871k ↗